Drug to slow Alzheimer's well tolerated outside of clinical trial setting, study finds
The Food and Drug Administration's approval in 2023 of lecanemab—a novel Alzheimer's therapy shown in clinical trials to modestly slow disease progression—was met with enthusiasm by many in the field as it represented ...
May 12, 2025
0
59